Arno Therapeutics, Inc.

ARNI

US0425642032

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:25:51 2024-04-23 am EDT			5-day change	1st Jan Change
0.0003 ^USD	+417.24%		+200.00%	+200.00%

2017	Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	CI
2017	Arno Therapeutics Seeks Acquisitions	CI

Arno Therapeutics, Inc. announced that it has received $2.725498 million in funding from Pontifax Ltd., OPKO Health, Inc., Perceptive Advisors LLC, Commercial Street Capital, LLC, Bonderman Family Limited Partnership, Auriga Capital Management, LLC

November 03, 2016

On November 4, 2016, Arno Therapeutics, Inc. (OTCPK:ARNI) closed the transaction. The company has issued 1,214,999 units for gross proceeds $425,250 in its last tranche. The company has issued 7,787,136 shares for gross proceeds of $2,725,498.

Latest news about Arno Therapeutics, Inc.

Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	17-12-25	CI
Arno Therapeutics Seeks Acquisitions	17-01-04	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	16-11-14	CI
Arno Therapeutics, Inc. announced that it has received $2.725498 million in funding from Pontifax Ltd., OPKO Health, Inc., Perceptive Advisors LLC, Commercial Street Capital, LLC, Bonderman Family Limited Partnership, Auriga Capital Management, LLC	16-11-03	CI
Arno Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	16-08-22	CI
Arno Therapeutics, Inc. Updates Clinical Development of Onapristone Plus Zytiga	16-08-16	CI
Arno Therapeutics, Inc. announced that it expects to receive $2.98 million in funding from a group of investors	16-08-14	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	16-05-17	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2015	16-03-30	CI
Arno Therapeutics, Inc. Appoints Jay Moorin to its Board of Directors	16-01-13	CI
Arno Therapeutics, Inc. announced that it has received $5.28 million in funding from Commercial Street Capital, LLC, and other investors.	16-01-11	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	15-11-16	CI
Arno Therapeutics, Inc. Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains	15-10-21	CI
Arno Therapeutics, Inc. announced that it expects to receive $2.1 million in funding from Commercial Street Capital, LLC and other investors.	15-10-20	CI
Arno Therapeutics, Inc. Announces Data Demonstrates Novel Antimicrobial Activity of AR-12	15-09-19	CI
Arno Therapeutics, Inc. Announces Resignation of Lawrence A. Kenyon as Chief Operating Officer and Chief Financial Officer, Effective September 15, 2015	15-09-11	CI
Arno Therapeutics, Inc. Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer	15-08-18	CI
Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015	15-08-14	CI
Arno Therapeutics, Inc. Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12	15-06-03	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015	15-05-15	CI
Arno Therapeutics, Inc. Announces Promising Data Supporting the Ongoing Clinical Development Program for Lead Compound Onapristone	15-05-13	CI
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone	15-05-07	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014	15-03-31	CI
Arno Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	15-03-30	CI
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014	14-12-09	CI

Chart Arno Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
ARNO THERAPEUTICS, INC.	+200.00%	14.8K
CSL LIMITED	-3.93%	86.16B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.17B
BIOGEN INC.	-16.48%	31.47B
UCB	+54.88%	25.24B
BIOMARIN PHARMACEUTICAL INC.	-13.58%	15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+5.62%	8.84B
INNOVENT BIOLOGICS, INC.	-2.11%	7.93B

Biopharmaceuticals